Nefopam Panpharma (Nefopam Hydrochloride)

Nefopam, the active ingredient in Nefopam Panpharma, is a non‑opioid analgesic presented as an injectable solution for intramuscular and intravenous use. It is employed to manage moderate acute pain and post‑operative pain in adult patients.

GNH USA supplies Nefopam Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to European Union quality standards, provides full regulatory documentation for global distribution, and follows GMP guidelines to ensure batch consistency and traceability for clinical use.

Nefopam is indicated for pain conditions that respond to central analgesic mechanisms.

- Moderate acute pain: provides effective analgesia without opioid‑related side effects. - Post‑operative pain: helps reduce the need for additional opioid rescue medication after surgery. - Surgical pain: assists in controlling pain following invasive procedures.

Nefopam may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Sweating: increased perspiration, especially during infusion. - Dizziness: transient light‑headedness or vertigo. - Dry mouth: reduced salivation. - Tachycardia: elevated heart rate during or shortly after administration.

Serious or Rare Side Effects: - Seizures: risk increased in patients with a seizure history. - Severe hypotension: sudden drop in blood pressure requiring monitoring. - Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmia: irregular heart rhythms in susceptible individuals.

When prescribing Nefopam, clinicians should consider several safety aspects.

- Renal impairment: monitor renal function and adjust therapy if needed. - Cardiovascular disease: use cautiously in patients with uncontrolled hypertension or arrhythmias. - History of seizures: avoid or use only under strict supervision. - Concomitant MAO inhibitors: contraindicated due to risk of serotonin syndrome. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nefopam can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants: increase risk of serotonergic toxicity. - Other serotonergic agents: combined use can lead to severe adverse reactions.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive blood‑pressure‑lowering effect. - Anticholinergic agents: may exacerbate dry mouth and urinary retention. - CYP450 inhibitors (e.g., fluoxetine): can raise plasma nefopam concentrations, requiring dose observation.